Video
The funding for the recombinant adjuvanted herpes zoster vaccine Shingrix has been broadened to include some with immunocompromise from 18 years of age. In this webinar, the role of the vaccine for those with immunocompromise will be reviewed.
Topics will include the epidemiology and clinical picture of herpes zoster, with an emphasis on those with different immunocompromising conditions.
The safety and effectiveness of the vaccine Shingrix will be reviewed with a focus on those with immunocompromise.
As always, we will answer as many questions as possible during this session.
Resources:
- Immunisation for adults with HIV infection - IMAC factsheet
- Immunisation for adults post-haematopoietic stem cell transplantation (HSCT) - IMAC factsheet
- Immunisation for adults pre-/post-solid organ transplantation (excluding kidney transplantation) - IMAC factsheet
- Immunisation for adults pre-dialysis, on dialysis or pre-/post-kidney transplantation - IMAC factsheet
- Funded vaccines for special groups from 1 July 2024 - IMAC factsheet
- Those at increased risk of HZ (appendix A) - Australian Government (Department of Health & Aged Care)
Presenter
Joan Ingram
Joan is an Infectious Diseases Physician with an interest in vaccines and vaccinations. She is a medical advisor with the Immunisation Advisory Centre (IMAC) at the University of Auckland and Infectious Diseases Physician at Te Toka Tumai (Auckland City Hospital). Her passion is the prevention of ill health with vaccinations and supporting those who do the mahi by providing information and supportive advice.
Presenter
Edwin Reynolds
Edwin is a general practitioner working in public health with a background in research who trained originally as an immunologist before studying medicine. He is a researcher and senior medical officer at the National Public Health Service (NPHS) – Northern Region, as well as a medical adviser to the Immunisation Advisory Centre (IMAC) for the last 15 years.
This medical education was commissioned and funded by GSK. The content was produced independently by the speaker(s) and The Goodfellow Unit
